SELECTIVE LABELING AND LOCALIZATION OF THE M4 (M4) MUSCARINIC RECEPTOR SUBTYPE

被引:0
|
作者
FERRARIDILEO, G
WAELBROECK, M
MASH, DC
FLYNN, DD
机构
[1] UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL R189,MIAMI,FL 33101
[2] UNIV MIAMI,SCH MED,DEPT NEUROL,MIAMI,FL 33101
[3] FREE UNIV BRUSSELS,SCH MED,DEPT BIOCHEM & NUTR,B-1000 BRUSSELS,BELGIUM
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We report here a novel strategy for the selective labeling and localization of the M4 (m4) muscarinic receptor subtype, based on the distinct kinetics of the muscarinic antagonists dexetimide and N-methylscopolamine (NMS) and on the selectivity profile of guanylpirenzepine and AF-DX 116 for the m1-m5 muscarinic receptor subtypes expressed in CHO-K1 cells. Incubation with 10 nM dexetimide, a nonselective antagonist, resulted in >90% occupancy of each of the m1-m5 receptor subtypes. The relatively rapid rates of dexetimide dissociation from the mi, m2, and m4 receptor subtypes (t(1/2) values of <12.5 min) and the slower rates of dexetimide dissociation from the m3 and m5 receptor subtypes (tn values of 65 and 75 min, respectively) favored the labeling of the mi, m2, and m4 receptor subtypes with short incubations with [H-3]NMS. Inclusion of 200 nM guanylpirenzepine and 250 nM AF-DX 116 prevented the binding of [H-3]NMS to the majority of the mi and m2 receptor subtypes, respectively, resulting in primary labeling of the m4 receptor subtype. Brief dissociation of the radioligand in the presence of 1 mu M atropine improved the ratio of m4 to m2 labeling by selectively removing [H-3]NMS from the m2 subtype. Under these conditions, the ratio of [H-3]NMS binding to the m4 versus mi, m2, m3, and m5 receptor subtypes was 4:1. In vitro autoradiography combined with these m4-selective labeling conditions demonstrated that the M4 (m4) receptor subtype was localized to the primary visual area (V1, area 17, occipital cortex) and the basal ganglia, a distribution distinct from that demonstrated for the M1 (mi), M2 (m2), and M3 (m3) receptor subtypes. These results demonstrate that a combination of the distinct kinetics of dexetimide and NMS and the receptor subtype selectivity of guanylpirenzepine and AF-DX 116 provides a valuable labeling strategy to examine the distribution and localization of the M4 (m4) muscarinic receptor subtype in brain, peripheral tissues, and cell lines.
引用
收藏
页码:1028 / 1035
页数:8
相关论文
共 50 条
  • [41] M4 MUSCARINIC RECEPTOR SUBTYPE ACTIVATES AN INWARDLY RECTIFYING POTASSIUM CONDUCTANCE IN ATT20 CELLS
    JONES, SVP
    NEUROSCIENCE LETTERS, 1992, 147 (02) : 125 - 130
  • [42] 'WARD M4'
    DAWE, B
    WESTERLY, 1993, 38 (02): : 40 - 40
  • [43] GUANYLPIRENZEPINE DISTINGUISHES BETWEEN NEURONAL M1 AND M4 MUSCARINIC RECEPTOR SUBTYPES
    MONFERINI, E
    CEREDA, E
    LADINSKY, H
    DONETTI, A
    GIRALDO, E
    JOURNAL OF RECEPTOR RESEARCH, 1990, 10 (1-2): : 81 - 96
  • [44] Cholinergic muscarinic M1/M4 receptor networks in dementia with Lewy bodies
    Colloby, Sean J.
    Nathan, Pradeep J.
    McKeith, Ian G.
    Bakker, Geor
    O'Brien, John T.
    Taylor, John-Paul
    BRAIN COMMUNICATIONS, 2020, 2 (02)
  • [45] The Muscarinic Acetylcholine Receptor Agonist BuTAC Mediates Antipsychotic-Like Effects via the M4 Subtype
    Marla L Watt
    Linda Rorick-Kehn
    David B Shaw
    Karen M Knitowski
    Anne T Quets
    Amy K Chesterfield
    David L McKinzie
    Christian C Felder
    Neuropsychopharmacology, 2013, 38 : 2717 - 2726
  • [46] Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor:: involvement of the M4 receptor subtype
    D'Agostino, G
    Bolognesi, ML
    Lucchelli, A
    Vicini, D
    Balestra, B
    Spelta, V
    Melchiorre, C
    Tonini, M
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (03) : 493 - 500
  • [47] Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice
    Gomeza, J
    Zhang, L
    Kostenis, E
    Felder, CC
    Bymaster, FP
    Brodkin, J
    Shannon, H
    Xia, B
    Duttaroy, A
    Deng, CX
    Wess, J
    LIFE SCIENCES, 2001, 68 (22-23) : 2457 - 2466
  • [48] Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor Subtypes
    Figueroa, Katherine W.
    Griffin, Michael T.
    Ehlert, Frederick J.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 328 (01): : 331 - 342
  • [49] THE DISTINCT PHARMACOLOGICAL PROFILE OF EMRACLIDINE, A SELECTIVE POSITIVE ALLOSTERIC MODULATOR OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
    Klein, Ellie
    Quinn, Angela
    Toh, May Fern
    Te, Leonard
    Catipay, Gwyneth
    Smith, Deborah L.
    Gupta, Kushali
    Hatch, Jamie
    Hanh Nguyen
    Iredale, Philip
    Pin, Sokhom
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 541 - 542
  • [50] BMW M4
    吕思达
    崔凯
    汽车与运动, 2015, (01) : 122 - 125